Organisation
Laboratory of Molecullar and Cellular Therapy
Research Group
The focus of the Laboratory for Molecular and Cellular Therapy (LMCT) is directed towards the application of basic immunological knowledge and molecular biotechnology for the understanding, diagnosis and treatment of human diseases, including cancer, infectious disease and brain disease.
Current researchers
1 - 10 of 35 results
- Karine Breckpot (Responsible)
- Dorien Autaers (Member)
- Robin Maximilian Awad (Member)
- Jonathan Bastos (Member)
- Thomas Benoot (Member)
- Sanne Bevers (Member)
- Hannelore Ceuppens (Member)
- Céline Coelis (Member)
- Lien De Beck (Member)
- Kirsten De Ridder (Member)
Projects
1 - 10 of 11
- GEAR: Brussels Liver Research to Valorisation Alliance (B-Liver): Valorisation of VUB’s liver cell biology and toxicology expertise via a consortium focused on liver therapeutics, patient and consumer safety.From1 Jan 2020 → TodayFunding: IOF - technology concept exploration, IOF - mandates
- GEAR: Integrating a multimodal approach to address current challenges in immunotherapy (INTEGRAL)From1 Jan 2020 → TodayFunding: IOF - technology validation in real environment, IOF - mandates
- Eccentric: Enhancing the function of Cancer Countering Effector cells using Nanobodies Targeting Regulatory Immune CheckpointsFrom1 Nov 2019 → 31 Oct 2023Funding: FWO fellowships
- Combining targeted radionuclide therapy and cancer immunotherapy to advance precision medicine through innovation.From1 Nov 2019 → 31 Oct 2023Funding: FWO fellowships
- A randomized phase II clinical trial in NSCLC combining SBRT and I.V. anti-PD-1 with or without I.T. anti-CTLA-4/anti-PD-L1 plus CD1c+ myDCFrom1 Oct 2019 → 30 Sep 2023Funding: FWO Applied Biomedical Research (TBM)
- Modulating epigenetic mechanisms to enhance cancer immunotherapy.From1 Oct 2018 → 30 Sep 2022Funding: FWO fellowships
- Target and explore the ‘X factor’ of the lung tumor microenvironment.From1 Jan 2018 → 31 Dec 2018Funding: FWO research grant KAN
- Strategic Research Programme: Cancer Cell Targeting in Myeloma and Melanoma (MyMe)From1 Nov 2017 → TodayFunding: University - Project driven research
- Evaluating a Combination of Immune-based Therapies to Achieve a Functional Cure of HIV Infection (HIVACAR)From1 Jan 2017 → 30 Jun 2022Funding: H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and wellbeing
- Rationally designed therapeutic vaccine against HIV-1 based on a novel formulation of nanoparticle-protected mRNAFrom1 Jan 2016 → 31 Dec 2018Funding: FWO research project (including WEAVE projects)
Publications
1 - 10 of 333
- Facilitated antigen uptake and timed exposure to TLR ligands dictate the antigen-presenting potential of plasmacytoid DCs.
Authors: M. Kool, C. Geurtsvankessel, F. Muskens, F.b. Madeira, M. Van Nimwegen, H. Kuipers, Kris Thielemans, H.c. Hoogsteden, H. Hammad, B.n. Lambrecht
Pages: 1177-1190 - mRNA: delivering an antitumor message?
Authors: Sandra Van Lint, Kris Thielemans, Karine Breckpot
Pages: 605-607 - Combinatorial strategies for the induction of immunogenic cell death.
Authors: L Bezu, LC Gomes-de-Silva, Heleen Dewitte, Karine Breckpot, J Fucikova, Radek Spisek, Lorenzo Galluzzi, Oliver Kepp, Guido Kroemer
- Characteristics, treatment, and virologic responses of chronic hepatitis C patients treated with peginterferon alfa-2a and ribavirin in belgium
Authors: J P Mulkay, Sophie Bourgeois, Luc Lasser, Chantal de Galocsy, S Tomasovic, Y. Horsmans, , Hendrik Reynaert
Pages: 30-40 - Corrigendum: "Combinatorial Strategies for the Induction of Immunogenic Cell Death"
Authors: Lucillia Bezu, Ligia C Gomes-da-Silva, Heleen Dewitte, Karine Breckpot, Jitka Fucikova, Radek Spisek, Lorenzo Galluzzi, Oliver Kepp, Guido Kroemer
- Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment
Authors: Heleen Dewitte, Rein Verbeke, Karine Breckpot, De Smedt Stefaan C., I. Lentacker
Pages: 743-758 - HIV-1 evolution in patients undergoing immunotherapy with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption
Authors: Anna De Goede, H.w. Van Deutekom, B. Vrancken, M Schutten, Carel A. Van Baalen, Ab D. Osterhaus, Joeri L Aerts, C. Kesmir, P. Lemey, Rob A. Gruters
Pages: 2679-2689 - Inefficient exogenous loading of a tapasin-dependent peptide onto HLA-B*44:02 can be improved by acid treatment or fixation of target cells(2012)
Authors: V. Stroobant, N. Demotte, R. M. Luiten, R. M. Leonhardt, P. Cresswell, Aude Bonehill, A. Michaux, W. Ma, A. Mulder, B.j. Van Den Eynde, et al.
Pages: 1417-1428 - Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula(2014)
Authors: Jurgen Corthals
Pages: 959-967 - A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption(2012)
Authors: Sabine D Allard, Brenda De Keersmaecker, A.l. De Goede, E.j. Verschuren, J. Koetsveld, M.l. Reedijk, C. Wylock, Annelies De Bel, Judith Vandeloo, F. Pistoor, et al.
Pages: 252-268